南方医科大学学报2017，Vol.37Issue(9)：1274-1279,6.DOI:10.3969/j.issn.1673-4254.2017.09.24
抗白细胞介素-17抗体治疗斑块状银屑病的系统评价
A systematic review of anti-interleukin-17 antibody in the treatment of plaque psoriasis
摘要
Abstract
Objective To evaluate the efficacy and safety of anti-interleukin-17 antibody in the treatment of plaque psoriasis.Methods Randomized controlled trials (RCT) of anti-interleukin-17 antibody (Secukinumab,Brodalumab,and Ixekizumab) in the treatment of plaque psoriasis published between January,2000 and March,2017 were searched from PubMed,Cochrane Library,EBSCO,EMbase,CBM,CNKI,VIPdetabase,and Wangfang database.The quality of the retrieved trials was evaluated and the results of studies were analyzed using RevMan 5.0 software.Results Thirteen RCTs were included involving a total of 11 203 patients.Meta-analysis showed a significant differences between anti-interleukin-17 antibody and placebo (or positive drug) in terms of PASI75 and sPGA (P＜0.05).The total incidence of adverse events differed significantly between antiinterleukin-17 antibody and placebo,but no significant differences were found between them in the incidence of serious adverse events and discontinuation rate due to adverse events (P＞0.05).Conclusion Anti-interleukin-17 antibody is safe and effective for treatment of plaque psoriasis.关键词
抗IL-17抗体/Secukinumab/Brodalumab/Ixekizumab/斑块状银屑病/Meta分析Key words
anti-interleukin-17 antibody/Secukinumab/Brodalumab/Ixekizumab/plaque psoriasis/meta-analysis引用本文复制引用
范小冬,向霞,张春燕,孔文强,周春阳,杜彪..抗白细胞介素-17抗体治疗斑块状银屑病的系统评价[J].南方医科大学学报,2017,37(9):1274-1279,6.基金项目
重庆市社会事业与民生保障科技创新专项(cstc2015shmszx120073) （cstc2015shmszx120073）
重庆市万州区科技计划基金资助项目(201403055) （201403055）
